CareCloud, Inc. (CCLD) is a healthcare information technology company that provides AI-powered technology solutions and revenue cycle management services to medical practices, health systems, and hospitals across the United States. The company operates through two primary segments, Healthcare IT and Medical Practice Management, and its portfolio spans revenue cycle management, practice management, electronic health records, business intelligence, patient experience management, and digital health services.
Through its 2025 Medsphere acquisition, CareCloud expanded into the inpatient hospital market, adding emergency department, inpatient EHR, and supply-chain products. Its AI offerings, including CirrusAI and the stratusAI suite, layer automation onto its clinical, financial, and operational platform, while MAP App — a benchmarking tool acquired from the Healthcare Financial Management Association (HFMA) — extends the company into hospital revenue cycle analytics. CareCloud serves tens of thousands of providers and positions itself as a full-stack, AI-driven technology partner for healthcare organizations seeking to streamline administrative work and improve financial performance.
Over the last 30 days, CareCloud shares delivered a sharp advance. The stock closed at $1.77 on October 14, 2026, and finished at $2.42 on November 13, 2026, a gain of approximately 36.7%. The move was concentrated around the company's third-quarter earnings release, with daily trading volume surging to nearly two million shares on November 5, 2026, well above its typical range. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The quarterly picture is more muted. CareCloud closed at $2.45 on August 13, 2026, meaning the stock was essentially flat — down about 1.2% — over the trailing three-month window ending November 13, 2026. The stock peaked near $2.66 in late August before a steady drift lower through September and October, touching a low around $1.71 in late October. The November earnings-driven rebound therefore represents a recovery from a multi-month pullback rather than a breakout to new highs.
The dominant catalyst was CareCloud's third-quarter 2026 earnings report, released on November 5, 2026, which the company described as its most profitable quarter in history. Revenue reached $33.7 million, up 9% year over year, while GAAP net income rose 54% to $4.7 million, GAAP EPS climbed 150% to $0.10, and adjusted EBITDA increased 28% to $9.9 million. The results marked a tenth consecutive quarter of positive GAAP net income, and the company reported GAAP EPS and revenue that exceeded consensus estimates. Management also reaffirmed full-year 2026 guidance, reinforcing investor confidence in the growth outlook.
Supporting the rally, CareCloud announced on November 11, 2026, an acceleration of its wound care expansion through new clients, EHR integration, and multimillion-dollar payer client audit wins. The company also reduced debt by $7.4 million during the quarter, while AI-enabled claims processing cut manual claim touches by 44%, highlighting improving operating efficiency. The appointment of Bonnie Boyer as Chief Financial Officer in late September 2026 added a management-level change ahead of the earnings inflection.
The broader three-month narrative was shaped by a mix of improving fundamentals and lingering uncertainty. Through 2026, CareCloud pursued an aggressive expansion strategy built on the Medsphere acquisition, new AI product launches, and a simplified capital structure — including a $50 million credit facility and the full redemption of its Series B preferred stock completed in May 2026. These moves reduced balance-sheet overhang and refocused capital toward growth.
At the same time, analyst sentiment through the first half of the year was cautious, with several firms trimming price targets on concerns that acquisition-driven revenue was masking softer organic growth and integration costs. The stock's drift lower from late August through October reflected this restrained outlook and broader small-cap healthcare IT pressure. The record third-quarter results, stronger margins, and reaffirmed guidance ultimately shifted the narrative, driving the sharp recovery that defined the final stretch of the quarter.
Looking ahead, the most important factor for CareCloud will be whether its profitability momentum continues into the fourth quarter and full-year 2026 results. Management has guided to revenue of $128 million to $132 million and GAAP EPS of $0.20 to $0.23 for 2026, so execution against those targets will be closely monitored. The pace of Medsphere integration and the roll-out of AI offerings such as stratusAI and CirrusAI represent key operational levers, while the expanding wound care business and payer audit wins offer incremental growth opportunities.
Investors should also watch analyst actions, which have ranged widely, reflecting divergent views on valuation and organic growth. Macroeconomic conditions, healthcare IT demand trends, and any developments around the company's balance sheet and debt reduction will remain relevant. As always, these factors carry risk as well as opportunity, and none of this constitutes financial advice or a prediction of future price performance.
In my experience following healthcare IT names, I’ve found value in reviewing automated strategies alongside traditional analysis. Tickeron’s AI Trading Bots provide a range of approaches that can highlight how different algorithms are responding to earnings-driven moves like the one seen in CCLD recently. This perspective helps round out the picture when evaluating short-term momentum versus longer-term trends.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
CCLD moved above its 50-day moving average on November 05, 2026 date and that indicates a change from a downward trend to an upward trend. In 37 of 43 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 86%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on CCLD as a result. In 77 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for CCLD just turned positive on October 29, 2026. Looking at past instances where CCLD's MACD turned positive, the stock continued to rise in 36 of 45 cases over the following month. The odds of a continued upward trend are 80%.
The 10-day moving average for CCLD crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +5.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where CCLD advanced for three days, in 190 of 229 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The 10-day RSI Indicator for CCLD moved out of overbought territory on November 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 20 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CCLD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
CCLD broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CCLD entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Seasonality Score of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. CCLD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.617) is normal, around the industry mean (4.523). P/E Ratio (32.857) is within average values for comparable stocks, (12.601). Projected Growth (PEG Ratio) (0.314) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.699) is also within normal values, averaging (6.105).
The Tickeron SMR rating for this company is 76 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CCLD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of medical billing and transcription services
Industry ServicestotheHealthIndustry